Walleye Capital
VNDA icon

Walleye Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Walleye Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-94,298
Closed -$445K – 5170
2025
Q2 		$445K Buy
94,298
+57,332
+155% +$251K ﹤0.01% 2743
2025
Q1 		$170K Buy
+36,966
New +$172K ﹤0.01% 3383
2024
Q2 		– Sell
-19,018
Closed -$78.2K – 6044
2024
Q1 		$78.2K Sell
19,018
-86,736
-82% -$347K ﹤0.01% 4514
2023
Q4 		$446K Sell
105,754
-152,193
-59% -$614K ﹤0.01% 3034
2023
Q3 		$1.11M Sell
257,947
-43,284
-14% -$240K ﹤0.01% 2172
2023
Q2 		$1.99M Sell
301,231
-14,138
-4% -$90.6K 0.01% 1337
2023
Q1 		$2.14M Buy
315,369
+168,329
+114% +$1.18M 0.03% 683
2022
Q4 		$1.09M Buy
+147,040
New +$1.43M 0.02% 954
2022
Q3 		– Sell
-194,164
Closed -$2.12M – 3570
2022
Q2 		$2.12M Buy
194,164
+130,114
+203% +$1.35M 0.06% 348
2022
Q1 		$724K Sell
64,050
-44,441
-41% -$584K 0.02% 804
2021
Q4 		$1.7M Buy
+108,491
New +$1.89M 0.05% 372

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Walleye Capital's VNDA Position: Q3 2025 in Review

Walleye Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 94,298 shares — an estimated $445K sold.

Walleye Capital first reported a position in VNDA in Q4 2021 and held it in 11 quarters. The position peaked at $2.14M in Q1 2023. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • Walleye Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 94,298 Vanda Pharmaceuticals shares in Q3 2025, an estimated $445K.
  • Walleye Capital first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Walleye Capital's Vanda Pharmaceuticals position peaked at $2.14M in Q1 2023.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.